High clinical heterogeneity in a Chinese pedigree of retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations (RVCL-S)

Nina Xie, Qiying Sun, Jinxia Yang, Yangjie Zhou, Hongwei Xu, Lin Zhou, Yafang ZhouOrphanet 2021 · DOI

Abstract

Our reports characterize a highly heterogeneous RVCL-S pedigree, highlight the probability of misdiagnosis in clinical practice, and broaden the clinical spectrum of RVCL-S.

Introduction

Retinal Vasculopathy with Cerebral Leukoencephalopathy and Systemic manifestations (RVCL-S) is a rare, autosomal dominant microvascular disorder. Caused by C-terminal frameshift mutations in the TREX1 gene, it primarily affects the small vessels of the brain, eyes, and kidneys. Due to its rarity and the way it presents on imaging, RVCL-S is frequently misdiagnosed as more common conditions, such as high-grade gliomas, multiple sclerosis, or systemic lupus erythematosus. This study examines a large Chinese pedigree to highlight the extreme clinical variability of the disease and identify new systemic symptoms.

Pedigree Analysis and Genetic Identification

The researchers conducted a comprehensive study of a four-generation Chinese family consisting of 26 members. Using Sanger sequencing, they identified a heterozygous C-terminal frameshift mutation, V235fs, in 13 family members.

Pedigree of the Chinese family and Sanger sequencing confirming the TREX1 V235fs mutation.

This genetic analysis formed the foundation for evaluating the clinical prevalence of the disease within the family. Among the 13 carriers, the most frequent manifestations were nephropathy (69%), hypertension (69%), and retinopathy (62%). Notably, the mean age of death in this pedigree was 43.1 years, significantly lower than the global average of 53.1 years, suggesting a potentially more aggressive disease course or delayed diagnosis in this population.

The "Clinical Chameleon": Diagnostic Challenges

A primary finding of this study is the extreme clinical heterogeneity observed even among individuals sharing the exact same genetic mutation. While some carriers presented only with isolated kidney disease, others suffered from multi-organ involvement.

One of the most significant hurdles in diagnosing RVCL-S is its radiological appearance. Magnetic Resonance Spectroscopy (MRS) patterns in these patients—characterized by decreased N-acetylaspartate (NAA), increased Choline, and lipid peaks—closely mimic high-grade gliomas. This often leads to unnecessary and potentially harmful brain surgeries or aggressive immunosuppressant therapies.

Multimodal imaging (CT, MRI, MRS) of brain lesions and abdominal CT showing mesenteric ischemia.

Broadening the Clinical Spectrum

The study identified mesenteric ischemia (chronic abdominal pain due to restricted blood flow in the gut) in the proband, a symptom not previously associated with RVCL-S. This discovery expands the known systemic reach of the disease beyond the brain, eyes, kidneys, and liver.

Furthermore, the researchers noted that symptomatic mutation carriers exhibited significantly higher levels of inflammatory markers, such as C-reactive protein (CRP) and Interleukin-6 (IL-6), compared to asymptomatic carriers. This supports the hypothesis that TREX1 mutations may trigger a pathological innate immune response, specifically through Type 1 interferon signaling.

Conclusion and Future Directions

This study underscores the importance of considering RVCL-S in the differential diagnosis of brain mass lesions, especially when accompanied by systemic microvascular involvement. Key diagnostic "red flags" identified include punctate calcifications on CT scans and central diffusion restriction on DWI MRI.

Future research should focus on developing non-invasive biomarkers to distinguish RVCL-S from gliomas and exploring the efficacy of anti-interferon therapies. Understanding why some mutation carriers remain asymptomatic for decades while others progress rapidly remains a critical area for investigation.

Summary updated

Abstract

Our reports characterize a highly heterogeneous RVCL-S pedigree, highlight the probability of misdiagnosis in clinical practice, and broaden the clinical spectrum of RVCL-S.
BibTeX
@inproceedings{xie2021high,
  author = {Nina Xie and Qiying Sun and Jinxia Yang and Yangjie Zhou and Hongwei Xu and Lin Zhou and Yafang Zhou},
  title = {{High clinical heterogeneity in a Chinese pedigree of retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations (RVCL-S)}},
  booktitle = {Orphanet},
  year = {2021},
  doi = {10.1186/s13023-021-01712-9},
}
Figure